Company / Cash & Equivalents
Cyclerion Therapeutics, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.2M
FY2025
5-year range
$3.2M / $54.0M
FY2021-FY2025
Trend
-57.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $8M to $3M over the past 2 years.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -43.1%.
Declined from $8M to $3M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -37.7%
- 5-Year CAGR
- -43.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -43.1%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 57.2% year-over-year.
- Peak cash & equivalents was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -19.82 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.2M | -57.2% |
| FY2024 | $7.6M | +0.0% |
| FY2023 | $7.6M | -43.4% |
| FY2022 | $13.4M | -75.2% |
| FY2021 | $54.0M | -0.8% |
| FY2020 | $54.4M | -42.7% |
| FY2019 | $94.9M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026